Global UAV Technologies to acquire Nexus Peptide Sciences via three-cornered amalgamation

Nuclea Energy to Go Public via Combination with Mangoceuticals

August 2, 2026

Energy

Nuclea Energy entered into a definitive business combination agreement with publicly traded Mangoceuticals to pursue a Nasdaq listing. The deal will be implemented through a newly formed indirect subsidiary of Mangoceuticals amalgamating with Nuclea, with former Nuclea shareholders expected to own about 96% of Mangoceuticals before a planned private investment.

Nexus Agriscience Acquires Biotech Institute Hemp Division IP Portfolio

January 27, 2026

Healthcare Services

Nexus Agriscience acquired the hemp division and associated intellectual property (IP) portfolio of Biotech Institute to expand its molecular farming platform. The deal includes issued and pending utility and plant patents, proprietary germplasm, seed inventory and living plant materials, with Biotech Institute leaders joining Nexus in governance and technical roles.

TA Associates (via Project Neptune BidCo) Completes Tender Offer to Acquire Nexus AG

January 3, 2025

Software

TA Associates, through its holding company Project Neptune BidCo GmbH, completed a tender offer to acquire approximately 94.95% of Nexus AG at €70.00 per share and expects settlement in Q1 2025 subject to regulatory clearances. TA plans to take Nexus private, delist it from the Frankfurt Stock Exchange, and support the company's growth by investing in R&D, cloud and AI capabilities and pursuing strategic acquisitions.

Invaio Sciences Acquires Peptyde Bio

December 7, 2023

Biotechnology

Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.

Alpine 4 Technologies Acquires Vayu (U.S.), Inc.

December 28, 2020

Aerospace & Defense

Alpine 4 Technologies, Ltd. entered into a binding LOI to acquire Vayu (U.S.), Inc., a maker of hybrid VTOL autonomous aircraft, in a reverse triangular merger that will make Vayu a wholly owned subsidiary. The deal adds VTOL aircraft, autopilot software and expanded capabilities to Alpine 4's aerospace holdings (complementing Impossible Aerospace) and is intended to accelerate medical delivery, infrastructure inspection and other commercial UAV opportunities; Vayu CEO Daniel Pepper will remain in place.

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.